HSBC Innovation Banking

"We solve one of the biggest problems in the real economy – suppliers and staff need to be paid on time, yet clients take time to pay."

"Our latest funding is a testament to both our commercial performance and belief in our long-term vision for providing personalised, preventative health at scale. With the fresh conviction of Big Pi Ventures, Endeavor Catalyst and HSBC Innovation Banking – as well as the continued backing of White Star Capital and our long-term investors – we are now perfectly positioned to expand our reach, deepen our clinical capabilities, and accelerate innovation to help our patients live happier, healthier, longer lives."

"With our funding product, we’re solving the challenge that tech companies so far would mostly use equity funding to fund their growth. This is a very costly capital source, as it comes with dilution and loss of control. Traditional banks rarely lend to unprofitable tech companies, and venture debt is usually only available for later-stage companies (and often comes with dilution/loss of control as well). With re:cap, tech companies starting from roughly 1m ARR get a flexible, tailored and transparent option to receive growth capital."

"As a profitable fintech operating at global scale, we have options when it comes to choosing how to invest for the next ten years of growth. This funding allows us to expand the range products we can offer our users and the channels through which we can reach them. HSBC Innovation Banking has been a key strategic partner to enable us to scale at pace and become one of the UK’s leading fintech brands."